212 related articles for article (PubMed ID: 11952539)
1. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity.
Miracco C; Margherita De Santi M; Schürfeld K; Santopietro R; Lalinga AV; Fimiani M; Biagioli M; Brogi M; De Felice C; Luzi P; Andreassi L
Br J Dermatol; 2002 Mar; 146(3):399-408. PubMed ID: 11952539
[TBL] [Abstract][Full Text] [Related]
2. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
3. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion.
Pathak S; Multani AS; McConkey DJ; Imam AS; Amoss MS
Int J Oncol; 2000 Dec; 17(6):1219-24. PubMed ID: 11078808
[TBL] [Abstract][Full Text] [Related]
5. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Guttman-Yassky E; Bergman R; Manov L; Sprecher E; Shaefer Y; Kerner H
J Cutan Pathol; 2002 Jul; 29(6):341-6. PubMed ID: 12135464
[TBL] [Abstract][Full Text] [Related]
6. In situ detection of telomeres by fluorescence in situ hybridization and telomerase activity in glioblastoma multiforme: correlation with p53 status, EGFR, c-myc, MIB1, and Topoisomerase IIalpha protein expression.
Miracco C; De Santi MM; Luzi P; Lalinga AV; Laurini L; De Nisi MC; Angeloni G; Brogi M; Cardone C; Carducci A; Arcuri F; Tosi P; Rubino G; Pirtoli L
Int J Oncol; 2003 Dec; 23(6):1529-35. PubMed ID: 14612923
[TBL] [Abstract][Full Text] [Related]
7. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
8. Nuclear pseudoinclusions in melanocytic naevi and melanomas.
Rose DS
J Clin Pathol; 1995 Jul; 48(7):676-7. PubMed ID: 7560180
[TBL] [Abstract][Full Text] [Related]
9. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma.
Ramirez RD; D'Atri S; Pagani E; Faraggiana T; Lacal PM; Taylor RS; Shay JW
Neoplasia; 1999 Apr; 1(1):42-9. PubMed ID: 10935469
[TBL] [Abstract][Full Text] [Related]
10. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Schmid P; Itin P; Rufli T
Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
[TBL] [Abstract][Full Text] [Related]
11. Detection of mRNA of Telomerase Protein in Benign Naevi and Melanomas Using RNAscope.
Baltzarsen PB; Georgsen JB; Nielsen PS; Steiniche T; Stougaard M
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):36-41. PubMed ID: 30095463
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.
Mourmouras V; Fimiani M; Rubegni P; Epistolato MC; Malagnino V; Cardone C; Cosci E; Nisi MC; Miracco C
Br J Dermatol; 2007 Sep; 157(3):531-9. PubMed ID: 17596146
[TBL] [Abstract][Full Text] [Related]
13. AgNOR area measurements differentiate benign and malignant melanocytic lesions more accurately than simple counting.
Gonzalez AP; Kumar D; Sánchez RL
Am J Dermatopathol; 1994 Aug; 16(4):372-6. PubMed ID: 7526724
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of telomerase activity in cutaneous melanocytic proliferations.
Miracco C; Pacenti L; Santopietro R; Laurini L; Biagioli M; Luzi P
Hum Pathol; 2000 Sep; 31(9):1018-21. PubMed ID: 11014565
[TBL] [Abstract][Full Text] [Related]
15. Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization.
Wettengel GV; Draeger J; Kiesewetter F; Schell H; Neubauer S; Gebhart E
Int J Oncol; 1999 Jun; 14(6):1177-83. PubMed ID: 10339676
[TBL] [Abstract][Full Text] [Related]
16. Application of fluorescence in situ hybridization as a diagnostic tool in melanocytic lesions, using paraffin wax-embedded tissues and imprint-cytology specimens.
Abásolo A; Vargas MT; Ríos-Martín JJ; Trigo I; Arjona A; González-Cámpora R
Clin Exp Dermatol; 2012 Dec; 37(8):838-43. PubMed ID: 22731835
[TBL] [Abstract][Full Text] [Related]
17. Moesin and CD44 expression in cutaneous melanocytic tumours.
Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
[TBL] [Abstract][Full Text] [Related]
18. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
[TBL] [Abstract][Full Text] [Related]
19. An assessment of the value of Ag NOR staining in the identification of dysplastic and other borderline melanocytic naevi.
MacKie RM; White SI; Seywright MM; Young H
Br J Dermatol; 1989 Apr; 120(4):511-6. PubMed ID: 2471546
[TBL] [Abstract][Full Text] [Related]
20. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
